Results of long-term therapy with growth hormone in two dose regimens in Turner syndrome. Dutch Growth Hormone Working Group.
Girls with Turner syndrome were divided according to age (group A 6-12 years, and group B 12-19 years) and human growth hormone (GH) dose regimen (A1 and B1, three injections/week; A2 and B2, six injections/week). All groups responded to GH, 24 IU/m2/week, with an increase in height velocity, though in the older girls, the response was comparatively poor. Therefore, the dose regimens in groups B1 and B2 were increased to 36 IU/m2/week given as six injections in both groups. This change resulted in an increase in height velocity only in group B1. During the first 2 years only, the height velocity was greater in group A2 than group A1. The conclusion is that a regimen of six injections/week is more effective than one of three injections/week in terms of initial height gain and change in predicted adult height. In girls with Turner syndrome aged over 16 years, GH therapy has no significant effect.
Nienhuis
H E
HE
Department of Paediatrics, University of Utrecth, The Netherlands.
Rongen-Westerlaken
C
C
Wit
J M
JM
Otten
B J
BJ
de Muinck Keizer-Schrama
S M
SM
Drayer
N M
NM
Delemarre-van de Waal
H A
HA
Vulsma
T
T
Oostdijk
W
W
Waelkens
J J
JJ
D000293:Adolescent; D000367:Age Factors; D001827:Body Height / Q000187:drug effects*; D001846:Bone Development / Q000187:drug effects; D002648:Child; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006128:Growth / Q000187:drug effects*; D013006:Growth Hormone / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007279:Injections, Subcutaneous; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use; D014424:Turner Syndrome / Q000188:drug therapy*
D011994:Recombinant Proteins; D013006:Growth Hormone